Kimia Biosciences Board Overhaul: New Director, MD Terms Changed

Kimia Biosciences Ltd. has made significant changes to its leadership and governance structure, announcing the appointment of a new director and revising the terms for its Managing Director.

Key Board Changes Announced

On April 18, 2026, Kimia Biosciences' Board of Directors approved several key updates. Ms. Richa Gupta stepped down as Independent Director on April 14, 2026, having completed her maximum term.

The board has appointed Mr. Amulya Kumar Nayak as a Non-Executive Additional Director. Mr. Nayak is a finance professional with over 32 years of experience, and his appointment requires shareholder approval.

Additionally, the board modified the re-appointment terms for Managing Director Mr. Sameer Goel and reconstituted its various committees.

Why the Changes Matter

Strong board composition is crucial for effective corporate oversight, guiding strategy, and maintaining investor confidence. The addition of Mr. Nayak, with his extensive finance background, is expected to bring valuable expertise and new perspectives to the board. The revisions to the Managing Director's terms and committee structures indicate the company's focus on adapting to current governance expectations and operational demands, which could influence future decisions and compliance efforts.

Company Background and Challenges

Kimia Biosciences is a pharmaceutical company involved in formulations and APIs. The company has faced financial challenges, as noted in its FY23 auditor report. The auditors raised a "going concern" issue, citing accumulated losses and a negative net worth, indicating uncertainty about the company's ability to continue operating. Past issues also included disputes among promoters and delays in regulatory filings. These factors highlight why stable, expert board leadership is important for the company's future.

What's Next for the Board and Management

Shareholders will vote on Mr. Amulya Kumar Nayak's appointment as a Non-Executive Additional Director. The revised terms for Managing Director Mr. Sameer Goel's re-appointment could affect his responsibilities or compensation. The reconstitution of board committees suggests potential adjustments in oversight roles or committee functions. These moves are part of Kimia Biosciences' ongoing efforts to reinforce its governance structure, especially given its past financial and operational challenges.

Key Risks to Monitor

A key risk is that Mr. Amulya Kumar Nayak's appointment as a Non-Executive Additional Director depends on shareholder approval, which will be sought at the upcoming General Meeting or via postal ballot. The company's underlying financial health, particularly the "going concern" uncertainty noted in the FY23 audit report, continues to be a significant factor affecting its long-term outlook.